BTMD Earnings Prediction
The chart below shows how BTMD performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BTMD sees a +2.61% change in stock price 10 days leading up to the earnings, and a -2.87% change 10 days following the report. On the earnings day itself, the stock moves by -1.93%. This data can give you a slight idea of what to expect for the next quarter's release.
BTMD Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
51.38M
12.79%
4.50%
Gross Margin
70.47%
2.28%
2.26%
Operating Margin
25.19%
0.84%
87.15%
Net Margin
24.63%
-42.88%
-215.63%
EPS
0.33
37.50%
-273.68%
No Data Available
BTMD Earnings Analysis
Biote Corp. Class A Common Stock Corporation (BTMD.O) Earnings Conference Call
Positive
Quarterly Revenue Increase: Total revenue in the third quarter was $51.4 million, up 12.8% from the prior quarter period.
Procedure Revenue Increase: Procedure revenue growth increased 7.1%, primarily reflecting growth of established top tier clinics and contribution from new clinics.
Dietary Supplement Revenue Growth: Third quarter dietary supplement revenue increased 21.7% year-over-year.
Gross Profit Margin Increase: Third quarter gross profit margin was 17.5%, a 160 basis point increase from the third quarter of 2023.
Net Income Analysis: Net income was $12.7 million, including a $7.2 million gain due to a change in the fair value of the earn-out liabilities.
Negative
Quarterly Revenue Increase: Total revenue in the third quarter was $51.4 million, up 12.8% from the prior quarter period.
Procedure Revenue Increase: Procedure revenue growth increased 7.1%, primarily reflecting growth of established top tier clinics and contribution from new clinics.
Procedure Volume Disruption: We experienced a temporary disruption in procedure volume towards the end of the third quarter as we introduced enhancements to our Clinical Decision Support software.
SG&A Cost Comparison: Selling, general and administrative costs were $24.0 million compared to $23.8 million in the third quarter of 2023.
SG&A Expense Moderation: As expected, third quarter SG&A expenses moderated on a sequential basis from the second quarter of 2024, as certain investments were incurred in the first half of the current year.
BTMD FAQs
How does BTMD typically perform around its earnings report dates?
Is biote Corp. (BTMD) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
BTMD Earning Call Sentiment
biote Corp. (BTMD) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
BTMD.O
0%Positive
The earnings call presents mixed signals. The financial performance shows solid growth in revenue and EPS, but the temporary disruptions from software updates and Hurricane Helene pose concerns. The Q&A reveals optimism about future growth, especially with BioteRx and Amazon, but unclear responses on profit margins and hurricane impacts raise uncertainties. The reiteration of revenue guidance and absence of a share repurchase program further contribute to a neutral sentiment, balancing positive financial growth with operational challenges and uncertainties.
